Law360, New York (November 02, 2006, 12:00 AM ET) -- Drug maker Warner Chilcott Ltd. deliberately failed to disclose that it had pulled one of its top earning drugs from shelves amid a federal antitrust investigation just days before its initial public offering, shareholders have alleged in a newly filed class action securities suit.
Filed by plaintiffs firm Lerach Coughlin Stoia Geller Rudman & Robbins in the U.S. District Court for the Southern District of New York, the complaint claims that Warner made misleading statements in its IPO prospectus, omitting details about a Federal Trade Commission...
Warner Chilcott Hit With Suit Over IPO Prospectus
To view the full article, take a free trial now.
